Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$0.28
$0.28
$0.00
▼
$2.49
$11.42M-1.91,039 shs100 shs
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.10
+1.9%
$1.29
$0.74
▼
$1.72
$34.59M0.27160,467 shs50,944 shs
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
$0.29
+0.2%
$0.31
$0.20
▼
$2.37
$46.15M0.294.69 million shs275,568 shs
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$0.63
-4.8%
$0.95
$0.62
▼
$1.67
$38.99M1.36552,621 shs157,221 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
0.00%+11,100.00%+39,900.00%-19.98%-87.98%
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-20.00%-32.08%-18.18%-3.57%-24.48%
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
+5.39%-5.64%-4.24%-1.36%-84.10%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
+0.12%-14.99%-26.45%-40.98%-57.90%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$0.28
$0.28
$0.00
▼
$2.49
$11.42M-1.91,039 shs100 shs
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.10
+1.9%
$1.29
$0.74
▼
$1.72
$34.59M0.27160,467 shs50,944 shs
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
$0.29
+0.2%
$0.31
$0.20
▼
$2.37
$46.15M0.294.69 million shs275,568 shs
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$0.63
-4.8%
$0.95
$0.62
▼
$1.67
$38.99M1.36552,621 shs157,221 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
0.00%+11,100.00%+39,900.00%-19.98%-87.98%
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-20.00%-32.08%-18.18%-3.57%-24.48%
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
+5.39%-5.64%-4.24%-1.36%-84.10%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
+0.12%-14.99%-26.45%-40.98%-57.90%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
0.00
N/AN/AN/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3.00
Buy$4.50309.09% Upside
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
2.13
Hold$1.67474.71% Upside
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
2.00
Hold$3.00376.95% Upside

Current Analyst Ratings Breakdown

Latest ANEB, MREO, ATNM, and PLRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
Reiterated RatingBuy$4.00
11/10/2026
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
Reiterated RatingBuy$1.00
10/15/2026
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
Reiterated RatingSell (E+)
9/29/2026
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
Reiterated RatingSell (E+)
8/19/2026
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
DowngradeNeutral ➝ Underweight
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/A$0.28 per shareN/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$35.09M0.99N/AN/A$1.31 per share0.84
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
$500K92.62N/AN/A$0.15 per share1.93
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/AN/AN/AN/A$2.04 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$8.48M-$0.19N/AN/AN/AN/AN/AN/AN/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$48.82M$0.33N/AN/AN/AN/A-100.85%-47.89%N/A
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
-$41.88M-$0.04N/AN/AN/AN/A-84.62%-71.44%N/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$149.34M-$1.45N/AN/AN/AN/A-57.13%-44.97%N/A

Latest ANEB, MREO, ATNM, and PLRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$0.3703-$0.39-$0.0197-$0.39N/AN/A
11/9/2026Q3 2026
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
-$0.01-$0.01N/A-$0.05$4.61 million$0.80 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/AN/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/AN/A
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
N/AN/AN/AN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/A
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/A
10.25
10.25
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
N/A
5.22
5.22
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/A
8.05
8.05

Institutional Ownership

CompanyInstitutional Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
28.40%
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
27.50%
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
62.83%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
97.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
340.79 million7.91 millionNot Optionable
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
2531.44 million29.32 millionOptionable
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
39159.69 million149.31 millionOptionable
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
4961.99 million56.57 millionOptionable

Recent News About These Companies

Pliant Therapeutics presents PLN-101095 data at SITC meeting
Pliant Therapeutics Inc Ordinary Shares PLRX

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anebulo Pharmaceuticals stock logo

Anebulo Pharmaceuticals OTCMKTS:ANEB

$0.28 0.00 (0.00%)
As of 11/18/2026 09:37 AM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Actinium Pharmaceuticals stock logo

Actinium Pharmaceuticals NYSE:ATNM

$1.10 +0.02 (+1.85%)
As of 11:52 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Mereo BioPharma Group stock logo

Mereo BioPharma Group NASDAQ:MREO

$0.29 +0.00 (+0.24%)
As of 11:55 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Pliant Therapeutics stock logo

Pliant Therapeutics NASDAQ:PLRX

$0.63 -0.03 (-4.84%)
As of 11:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.